This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Jenike, M. A. Articles by Gunther, J. Search for Related Content PubMed Articles by Jenike, M. A. Articles by Gunther, J. Social Bookmarking                         What's this?

Oral Physostigmine as Treatment for Primary Degenerative Dementia: A Double-Blind Placebo-Controlled Inpatient Trial

Division on Aging, Harvard Medical School, and the Department of Psychiatry, Massachusetts General Hospital, Boston, MA

Marilyn Albert

Division on Aging, Harvard Medical School, and the Department of Psychiatry, Massachusetts General Hospital, Boston, MA

Lee Baer

Division on Aging, Harvard Medical School, and the Department of Psychiatry, Massachusetts General Hospital, Boston, MA

Jeanette Gunther

Division on Aging, Harvard Medical School, and the Department of Psychiatry, Massachusetts General Hospital, Boston, MA

Twenty-three patients with primary degenerative dementia (Alzheimer's disease) were administered an optimal dose of oral physostigmine and placebo, each for a 1-week period, under double-blind conditions on a research unit of a general hospital. Each patient served as his or her own control. The optimal dose of physostigmine for each patient was determined previously by a dose-finding phase. There were no significant group differences on a number of neuropsychological tests. Along with other studies in the literature, this study casts serious doubt on the efficacy of short-term administration of oral physostigmine when used alone in an attempt to ameliorate cognitive dysfunction in Alzheimer's disease patients. The possibilities that physostigmine may slow the course of the disease or may acutely improve symptoms when combined with other agents are discussed. (J Geriatr Psychiatry Neurol 1990;3:13-17).

Journal of Geriatric Psychiatry and Neurology, Vol. 3, No. 1, 13-16 (1990)
DOI: 10.1177/089198879000300104


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Tacrine for Alzheimer's Disease: A More Definitive Report J Geriatr Psychiatry Neurol, January 1, 1993; 6(1): 59 - 60. [PDF]